10 Sept 2019 Inventiva announces the positive recommendation of the 4 th and last DSMB of the Phase IIb clinical study with lanifibranor in NASH

4 September 2019 Inventiva achieves a major milestone by completing patient recruitment for its Phase IIb clinical study with lanifibranor in NASH

28 August 2019 Inventiva secures a new European patent strengthening and extending the protection of its lead product candidate lanifibranor

27 August 2019 New promising results on lanifibranor to be presented at The Liver Meeting® 2019

20 August 2019 Inventiva secures new patent in the US strengthening the protection of its lead product candidate lanifibranor

23 May 2019 Inventiva announces that FDA lifts target class clinical hold which allows long-term clinical studies with lanifibranor in NASH

21 February 2019 Inventiva announces further progress achieved in the clinical development of lanifibranor for the treatment of NASH

24 September 2018 Inventiva launches an independent working group to help increase NASH awareness and establish best practices for its treatment

30 August 2018 : Inventiva advances in the development of lanifibranor with the achievement of three key milestones

13 August 2018 : Inventiva’s lanifibranor found to have good safety profile following first assessment of carcinogenicity studies’ results

10 july 2018 : Inventiva Announces Positive DSMB Reviews in both NASH and Systemic Sclerosis Phase IIb Trials with Lanifibranor

20 june 2018 : FDA Approval of an Investigator Initiated IND Application to Conduct Phase II Study of Lanifibranor in Type 2 Diabetic Patients with Non-Alcoholic Fatty Liver Disease

3 april 2018 : Inventiva Announces a U.S. Phase II Investigator-Initiated Study with Lanifibranor on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes

28 march 2018 : Lanifibranor carcinogenicity studies: Progressing as planned and interim results in rats indicate no compound related urinary bladder tumors

13 march 2018 :  Inventiva’s paper on the discovery and synthesis of its panPPAR agonist lanifibranor accepted and published in the Journal of Medicinal Chemistry of the American Chemical Society

18 Sep 2017: Inventiva’s IVA337 Given Generic Name “Lanifibranor” by the World Health Organization (WHO)

27 Jul 2017: Inventiva to Present New Data on IVA337 at the 15th International Workshop on Scleroderma Research in Pittsburgh, USA

20 Jun 2017: Inventiva Announces Peer Review Publication of IVA337 Data in Pre-Clinical NASH Models

15 May 2017: Inventiva Announces Positive Results of 12 Month Primate Toxicity Study with IVA337

20 Apr 2017: Inventiva Announces Presentation of Preclinical Results on IVA337 in NASH at the International Liver Congress™ 2017 (EASL)

3 Jan 2017:  Inventiva Announces Initiation of Phase IIb Clinical Trial of IVA337 for Treatment of Non-Alcoholic Steatohepatitis (NASH)